跳至主要内容
临床试验/DRKS00014562
DRKS00014562已完成不适用

on-interventional study on the usage and outcomes of CUVITRU in patients with Primary Immunodeficiency Diseases - CORE CUVITR

GWT-TUD GmbH, Abteilung Medizin0 个研究点目标入组 36 人开始时间: 2018年4月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • 1. Patient with a documented diagnosis of a form of primary humoral immunodeficiency (PID) involving a defect in antibody formation and requiring gammaglobulin replacement
  • 2. Subject has received any SCIG (subcutaneous immunoglobulin) product previous to CUVITRU for at least 3 month at a stable dose
  • 3. Subject has received CUVITRU in line with the product specification (labelling) at the time of first documentation and is expected to continue treatment with this therapy in future
  • 4. Subject or legally authorized representative has provided written informed consent
  • 5. Subject is likely and willing to be available for follow-up documentation including patient-reported assessments

排除标准

  • 1. Subject has experienced a dose change during 3 month previous to the time of CUVITRU initiation
  • 2. Subject participates in a clinical study in parallel during the observation period

研究者

发起方
GWT-TUD GmbH, Abteilung Medizin

相似试验